CVS Health (CVS) Wolfe Research 2024 Healthcare Conference summary

Leadership and strategic direction

• Recent management changes include a new CEO and President, both with deep industry experience and internal track records.

• Four new board members have joined, with support from key shareholders and a focus on constructive collaboration.

• Leadership was instrumental in launching CostVantage and TrueCost, aiming to reshape industry pricing models.

Financial performance and outlook

• Third quarter performance showed improvement over the second quarter, with cost trends moderating.

• Medicare business experienced high cost trends, especially in Q2, leading to a cautious outlook for 2024.

• No formal guidance for 2025 yet, as variability in cost trends and membership mix remains a key consideration.

Segment-specific updates and strategies

• Medicaid business expected to improve as rate adjustments catch up, but target margins unlikely before late 2025 or 2026.

• Individual exchange segment faces losses but is expected to progress toward profitability, with potential market exits if targets are not met.

• Medicare segment to benefit from Stars improvement, product redesigns, and capped supplemental benefits, with margin improvement opportunities identified.